The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(8), P. 3328 - 3338

Published: May 23, 2024

Abstract Aim Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are at increased risk of incident cardiovascular disease. However, the clinical characteristics and prognostic importance MASLD in patients presenting acute myocardial infarction (AMI) have yet to be examined. Methods This study compared outcomes without AMI a tertiary centre Singapore. was defined as hepatic steatosis, least one five criteria. Hepatic steatosis determined using Steatosis Index. Propensity score matching performed adjust for age sex. The Kaplan‐Meier curve constructed long‐term all‐cause mortality. Cox regression analysis used investigate independent predictors Results In this 4446 AMI, 2223 were matched propensity scores. mean follow‐up duration 3.4 ± 2.4 years. group had higher rates obesity, diabetes chronic kidney than their counterparts. early excess mortality (6.8% vs. 3.6%, p < .001) 30 days, unfavourable sustained (18.3% 14.5%, = those MASLD. After adjustment, remained independently associated (hazard ratio 1.330, 95% confidence interval 1.106‐1.598, .002). Conclusion embodies burden dysfunction is an predictor population. Its identification may beneficial stratification provide therapeutic targets secondary preventive strategies AMI.

Language: Английский

---

Mortality, Cardiovascular, and Medication Outcomes in Patients With Myocardial Infarction and Underweight in a Meta-Analysis of 6.3 Million Patients

The American Journal of Cardiology, Journal Year: 2023, Volume and Issue: 196, P. 1 - 10

Published: April 5, 2023

Language: Английский

---

Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction

Diabetes Obesity and Metabolism, Journal Year: 2022, Volume and Issue: 25(4), P. 1032 - 1044

Published: Dec. 22, 2022

To examine the prevalence and prognosis of hepatic steatosis fibrosis in post-acute myocardial infarction (AMI) patients.Patients presenting with AMI to a tertiary hospital were examined from 2014 2021. Hepatic advanced determined using Steatosis Index fibrosis-4 index, respectively. The primary outcome was all-cause mortality. Cox regression models identified determinants mortality after adjustments Kaplan-Meier curves constructed for mortality, stratified by fibrosis.Of 5765 patients included, 24.8% had steatosis, whom 41.7% diagnosed fibrosis. median follow-up duration 2.7 years. Patients tended be younger, female, elevated body mass index an increased metabolic burden diabetes, hypertension hyperlipidaemia. (24.6% vs. 20.9% P < .001) (45.6% 32.9% higher rates compared their respective counterparts. (adjusted hazard ratio 1.364, 95% CI 1.145-1.625, = associated adjustment confounders. Survival showed excess those without (P .002).Hepatic have substantial among AMI. Both are incrementally risk when ensues. could help stratification beyond conventional factors.

Language: Английский

---

Examining the interim proposal for name change to steatotic liver disease in the US population

Hepatology, Journal Year: 2023, Volume and Issue: 77(5), P. 1712 - 1721

Published: Jan. 3, 2023

Fatty liver is the commonest condition globally and traditionally associated with NAFLD. A consensus meeting was held in Chicago to explore various terminologies. Herein, we proposed changes nomenclature a population data set from US.Statistical analysis conducted using survey-weighted analysis. Assessment of fatty vibration-controlled transient elastography. controlled attenuation parameter 288 dB/m used identify hepatic steatosis. Patients were classified into nonalcoholic steatotic disease, alcohol-associated viral hepatitis disease. Liver stiffness measures at ≥8.8, ≥11.7, ≥14 kPa clinically significant fibrosis, advanced cirrhosis, respectively. total 5102 individuals included Using analysis, 25.43%, 6.95%, 0.73% as sensitivity 248 index found similar distribution. In comparison between there no difference odds fibrosis cirrhosis groups. However, disease have significantly higher (OR: 3.76, 95% CI, 1.27-11.14, p =0.02) compared disease.The current assessed based on discussions meeting. Although definitions are an interim discussions, respects underlying etiology reduces stigma while increasing awareness FL among steatosis/steatohepatitis.

Language: Английский

---

Editorial: The heart of NAFLD

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: May 22, 2023

EDITORIAL article Front. Med., 22 May 2023Sec. Gastroenterology Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1209625

Language: Английский

---

Hepatic steatosis and advanced fibrosis are independent predictors of mortality in acute myocardial infarction without standard modifiable risk factors

Diabetes Obesity and Metabolism, Journal Year: 2022, Volume and Issue: 24(12), P. 2454 - 2458

Published: July 18, 2022

Language: Английский

---

General Public’s knowledge, awareness, and perception of Cardiometabolic diseases: data from a Singapore study population

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: April 24, 2023

Health literacy and illness perception play crucial roles in tackling the cardiometabolic disease epidemic. We aim to compare attitudes, knowledge, self-perceived risks actions taken, between individuals with without metabolic risk factors (MFs).From 5 June October 2022, participants of general public were invited complete a self-administered questionnaire. MF status was defined as presence hypertension, hyperlipidemia, diabetes mellitus and/or current/previous smoking. Participants assessed based on four categories (knowledge-based, attitude-based, perceived risk, action-based) questions pertaining diseases - mellitus, non-alcoholic fatty liver disease.A total 345 enrolled, whom 34.5% had at least one MF. Compared those MFs, MFs lower knowledge scores, but higher scores across all diseases. The largest gap pertained hypertension-related questions. After adjustment, linear regression demonstrated that (β:2.752, 95%CI: 0.772-4.733, p = 0.007) (β:0.418, 0.236-0.600, < 0.001) associated risk. Despite increased this translated only few self-reported preventive actions, when compared namely reduction red meat/processed food consumption (p 0.045) increase fruits/vegetables 0.009).This study identified vulnerable subpopulation living high risks, discordant levels taken. Nationwide efforts should be channeled into addressing knowledge-to-action gap.

Language: Английский

---

Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis

European Journal of Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 264, P. 115992 - 115992

Published: Nov. 27, 2023

Language: Английский

---

Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors

Clinical Research in Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 12, 2024

Language: Английский

---

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist

Drugs in R&D, Journal Year: 2023, Volume and Issue: 23(4), P. 453 - 464

Published: Nov. 2, 2023

ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty disease/nonalcoholic steatohepatitis (NAFLD/NASH) and primary biliary cirrhosis (PBC).The objective of this study was to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) healthy subjects.We conducted first-in-human following single multiple ascending doses (SAD/MAD) food effect subjects. The SAD included five cohorts receiving 5-200 mg or placebo one cohort that given 15 with high-fat meal. MAD three 5-50 once-daily (QD) 14 days.A total 65 subjects were enrolled subject (cohort 8, 50 mg) withdrew from due an unrelated serious adverse event (SAE) atrial fibrillation. Pruritus observed at highest (200 MAD). Most AEs mild moderate. No life-threatening fatal occurred. showed proportional increase exposure elimination half-life both dosing. There 21% 37% decrease area under curve (AUC) maximum plasma concentration (Cmax) when coadministered food. steady state reached on day 4 accumulation (1.02-1.74-fold). dose-dependent increases fibroblast growth factor 19 decreases 7α-hydroxy-4-cholesten-3-one. Cholesterol remained within normal limits during study.ASC42 well tolerated pharmacokinetic profile suitable QD dosing, demonstrated targets engagement without altering cholesterol subjects.NCT04679129.

Language: Английский

---